Taken together, our results suggest that although GM-CSF is a possible therapeutic molecule for treating patients with autoimmune idiopathic PAP, it may not be suitable for treating PAP in LPI patients. The gene discussed is CSF2; the disease is pulmonary alveolar proteinosis.